JP2011508595A - 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子 - Google Patents

外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子 Download PDF

Info

Publication number
JP2011508595A
JP2011508595A JP2010540954A JP2010540954A JP2011508595A JP 2011508595 A JP2011508595 A JP 2011508595A JP 2010540954 A JP2010540954 A JP 2010540954A JP 2010540954 A JP2010540954 A JP 2010540954A JP 2011508595 A JP2011508595 A JP 2011508595A
Authority
JP
Japan
Prior art keywords
amino acid
pcv2
composition
acid segment
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010540954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011508595A5 (fr
Inventor
エリック ヴォーン
メリル シェーファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Animal Health USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health USA Inc filed Critical Boehringer Ingelheim Animal Health USA Inc
Publication of JP2011508595A publication Critical patent/JP2011508595A/ja
Publication of JP2011508595A5 publication Critical patent/JP2011508595A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
JP2010540954A 2007-12-31 2008-12-31 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子 Pending JP2011508595A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1786307P 2007-12-31 2007-12-31
PCT/US2008/088678 WO2009088950A2 (fr) 2007-12-31 2008-12-31 Particule de type virus pcv2 orf2 avec insertion d'acides aminés étrangers

Publications (2)

Publication Number Publication Date
JP2011508595A true JP2011508595A (ja) 2011-03-17
JP2011508595A5 JP2011508595A5 (fr) 2012-03-22

Family

ID=40853690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540954A Pending JP2011508595A (ja) 2007-12-31 2008-12-31 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子

Country Status (9)

Country Link
US (2) US20110020394A1 (fr)
EP (1) EP2231182A4 (fr)
JP (1) JP2011508595A (fr)
KR (1) KR20100103535A (fr)
CN (1) CN101932336B (fr)
AU (1) AU2008347235A1 (fr)
BR (1) BRPI0821456A2 (fr)
CA (1) CA2710558A1 (fr)
WO (1) WO2009088950A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088950A2 (fr) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Particule de type virus pcv2 orf2 avec insertion d'acides aminés étrangers
CN101773667A (zh) * 2010-01-28 2010-07-14 洛阳普莱柯生物工程有限公司 一种猪圆环病毒ii型疫苗制备
KR102153365B1 (ko) * 2018-03-19 2020-09-08 주식회사 옵티팜 신규한 바이러스 유사입자, 이를 포함하는 돼지 써코바이러스 3에 의한 질환에 대한 백신 조성물, 및 이의 제조 방법
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1579553A (zh) * 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
WO2006068663A2 (fr) * 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2007076520A2 (fr) * 2005-12-29 2007-07-05 Boehringer Ingelheim Vetmedica, Inc. Compositions immunogenes pcv2 multivalentes, et procede de production de telles compositions

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202430A (en) * 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
GB9023111D0 (en) * 1990-10-24 1990-12-05 Wellcome Found Expression system
WO1992007934A1 (fr) * 1990-11-01 1992-05-14 Iowa State University Research Foundation, Inc. Procede d'attenuation bacterienne et vaccin
US5580557A (en) * 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5885823A (en) * 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
DK0835930T3 (da) * 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
US5735555A (en) * 1996-12-18 1998-04-07 Siemens Automotive Corporation Fuel rail to fuel tube end compact connector
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
PT2363488E (pt) * 1997-12-11 2015-01-13 Univ Belfast Síndrome multi-sistémica do definhamento pós-desmame de porcos
US6287856B1 (en) * 1998-03-13 2001-09-11 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6294176B1 (en) * 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6808900B2 (en) * 2000-06-15 2004-10-26 Manitoba, University Of Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
RU2312142C2 (ru) * 2001-03-27 2007-12-10 Юниверсити Оф Саскачеван Способы культивирования цирковирусов
US20030096377A1 (en) * 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
ATE412426T2 (de) * 2001-07-02 2008-11-15 Pfizer Prod Inc Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) * 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US20030215455A1 (en) * 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
US7223207B1 (en) * 2002-09-13 2007-05-29 Simon Basyuk Exercise and massage device
CN1458167A (zh) * 2003-06-02 2003-11-26 中国农业科学院哈尔滨兽医研究所 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
DE602004013331T2 (de) * 2003-07-24 2009-07-16 Merial Ltd. Vakzin-formulierungen mit einer öl-in-wasser-emulsion
DK1651260T4 (en) * 2003-07-25 2018-10-08 Boehringer Ingelheim Vetmedica Inc Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods for their use
FR2861731B1 (fr) * 2003-10-30 2006-02-24 Centre Nat Rech Scient Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) * 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
BRPI0606539A2 (pt) * 2005-01-13 2009-06-30 Boehringer Ingelheim Vetmedica Gmbh vacinas aperfeiçoadas contra a prrs
US7300785B2 (en) * 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en) * 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CA2604691C (fr) * 2005-04-13 2013-12-31 Merial Limited Dosage destine a la production de circovirus porcin
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
DK2371382T3 (en) * 2005-12-29 2016-06-13 Boehringer Ingelheim Vetmedica Inc Use of a PCV2 immunogenic composition to reduce the clinical signs in swine
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009088950A2 (fr) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Particule de type virus pcv2 orf2 avec insertion d'acides aminés étrangers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1579553A (zh) * 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
WO2006068663A2 (fr) * 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2007076520A2 (fr) * 2005-12-29 2007-07-05 Boehringer Ingelheim Vetmedica, Inc. Compositions immunogenes pcv2 multivalentes, et procede de production de telles compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013032991; Ｖｅｔ．　Ｒｅｓ．　Ｃｏｍｍｕｎ． Ｖｏｌ．　３１, 200705, ｐ．　４８７-４９６ *
JPN6013032993; Ｔｒｅｎｄｓ　Ｍｉｃｒｏｂｉｏｌ． Ｖｏｌ．　１１，　Ｎｏ．　９, 2003, ｐ．　４３８-４４４ *
JPN6013032995; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ．　ＵＳＡ． Ｖｏｌ．　９４, 1997, ｐ．　７５０３-７５０８ *
JPN6013032996; Ｉｎｆｅｃｔ．　Ｉｍｍｕｎ． Ｖｏｌ．　６８，　Ｎｏ．　５, 2000, ｐ．　２６０８-２６１６ *
JPN6013032998; Ｖａｃｃｉｎｅ Ｖｏｌ．　２２, 2004, ｐ．　２９９３-３００３ *
JPN6013032999; Ｐｒｏｔｅｉｎ　Ｅｘｐｒ．　Ｐｕｒｉｆ． Ｖｏｌ．　２１, 2001, ｐ．　１１５-１２０ *

Also Published As

Publication number Publication date
CN101932336A (zh) 2010-12-29
CA2710558A1 (fr) 2009-07-16
AU2008347235A1 (en) 2009-07-16
CN101932336B (zh) 2014-07-09
EP2231182A2 (fr) 2010-09-29
US20150202282A1 (en) 2015-07-23
KR20100103535A (ko) 2010-09-27
WO2009088950A2 (fr) 2009-07-16
US20110020394A1 (en) 2011-01-27
BRPI0821456A2 (pt) 2015-06-16
EP2231182A4 (fr) 2012-08-22
WO2009088950A3 (fr) 2009-10-08

Similar Documents

Publication Publication Date Title
JP7445375B2 (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
US20200237894A1 (en) Pcv2 orf2 carrier platform
US20220031831A1 (en) Immunogenic compositions for african swine fever virus
AU2016219738B2 (en) Designer peptide-based PCV2 vaccine
US20140348874A1 (en) Method for the reduction of pcv-2 in a herd of swine
US11896659B2 (en) Porcine Circovirus Type 3 (PCV3) vaccines, and production and uses thereof
WO2002040681A1 (fr) Fragment polypeptidique du virus de l'hepatite e, composition vaccinale contenant ledit fragment, agent diagnostic et leurs applications
US20150202282A1 (en) Pcv2 orf2 virus like particle with foreign amino acid insertion
US20230167159A1 (en) Sars-coronavirus 2 (sars-cov-2) subunit vaccine candidates
KR20230123463A (ko) 재조합 고전적 돼지 열 바이러스 e2 단백질
RU2803427C1 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
WO2022246449A1 (fr) Vaccins à sous-unité de protéine de spicule de sars-coronavirus 2 (sars-cov-2)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140303